Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
Journal of Molecular Biology|August 22, 2006
Genetic selection for critical residues in ribonucleasesBryan D Smith, Ronald T RainesProtein Engineering, Design & Selection : PEDS|March 1, 2008
Genetic selection for peptide inhibitors of angiogeninBryan D Smith, Ronald T RainesThe Journal of Biological Chemistry|March 22, 2003
Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid)Bryan D Smith, Matthew B Soellner, Ronald T RainesLangmuir : the ACS Journal of Surfaces and Colloids|December 29, 2004
Synthetic surfaces for ribonuclease adsorptionBryan D Smith, Matthew B Soellner, Ronald T RainesBioorganic & Medicinal Chemistry Letters|May 17, 2011
Site-specific folate conjugation to a cytotoxic proteinBryan D Smith, Joshua J Higgin, Ronald T RainesThe FEBS Journal|January 6, 2011
Functional and structural analyses of N-acylsulfonamide-linked dinucleoside inhibitors of RNase ANethaji Thiyagarajan, Bryan D Smith, Ronald T Raines, et al.Molecular Cancer Therapeutics|May 5, 2021
Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic MastocytosisAnu Gupta, Jarnail Singh, Alfonso García-Valverde, et al.Neuro-Oncology|March 12, 2016
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse modelsYuji Piao, Soon Young Park, Verlene Henry, et al.Future Oncology (London, England)|August 18, 2023
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumorWilliam D Tap, Maitreyi G Sharma, Marc Vallee, et al.Elife|August 30, 2024
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancerPhaedra C Ghazi, Kayla T O'Toole, Sanjana Srinivas Boggaram, et al.Pageof 3